All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Glasdegib receives approval from the European Commission for the treatment of adult patients with newly diagnosed AML

Jul 6, 2020
Share:

On June 30, 2020, the European Commission approved glasdegib, an oral smoothened inhibitor, in combination with low-dose cytarabine (LDAC) for the treatment of newly diagnosed de novo or secondary acute myeloid leukemia (AML) in patients ineligible for standard chemotherapy. This approval follows the positive opinion received from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use and the approval by the U.S. Food and Drug Administration (FDA). The European Commission’s approval was based on the results from the phase II BRIGHT 1003 trial (NCT01546038).1 Follow-up data and 4-year overall survival from this trial were recently presented as an e-poster at the 25th European Hematology Association Annual Congress.

Study design1–3

  • Randomized, open-label phase II trial in patients with previously untreated de novo or secondary AML who were not eligible to receive intensive chemotherapy
  • 116 patients with AML were randomized 2:1 to receive glasdegib + LDAC (n = 78) or LDAC alone (n = 38)
  • Glasdegib was administered at 100 mg, once daily, continuously for 28 days
  • LDAC was administered at 20 mg/m2, twice daily, on Days 1–10 of a 28-day cycle
  • Outcome measures: Overall survival (OS), complete response (CR), tolerability, and toxicities

Results1,3

  • Treatment with glasdegib approximately doubled the median OS compared with LDAC alone (8.3 vs 4.3 months, respectively; HR, 0.53; 95% CI, 0.35–0.80; p = 0.002)
    • This trend was also true whether patients had de novo AML (6.6 vs 4.3 months, respectively; HR, 0.75; 95% CI, 0.41–1.36; p = 0.337) or secondary AML (9.1 vs 4.1 months, respectively; HR, 0.29; 95% CI, 0.15–0.55; p < 0.001) and across subgroups of cytogenetic risk
  • Complete response (CR)/CR with incomplete hematologic recovery (CRi) rates were higher in the glasdegib + LDAC cohort vs the LDAC alone cohort (22.4% vs 5.3%, respectively)
    • The median time to CR/CRi in the respective cohorts was 60 days vs 162 days
  • The most frequently reported adverse events in patients receiving glasdegib can be seen in Table 1
    • Those that led to dose reductions included muscle spasms (4.7%), fatigue (3.5%), febrile neutropenia (3.5%), anemia (2.3%), thrombocytopenia (2.3%), and prolonged QT electrocardiogram (2.3%)
    • Those that led to permanent discontinuation included pneumonia (5.9%), febrile neutropenia (3.5%), and nausea (2.3%)

 Table 1. Most frequently reported hematological and non-hematological adverse events in patients receiving glasdegib

Adverse event

% of patients

(n = 78)

Hematological

 

Anemia

45.2

Hemorrhages

45.2

Febrile neutropenia

35.7

Thrombocytopenia

30.9

Non-hematological

 

Nausea

35.7

Decreased appetite

33.3

Fatigue

30.9

Muscle spasms

30.9

Pyrexia

29.7

Diarrhea

28.5

Pneumonia

28.5

Dysgeusia

26.1

Peripheral edema

26.1

Constipation

25.0

Abdominal pain

25.0

Rash

25.0

Dyspnea

25.0

Vomiting

21.4

Decreased weight

20.2

 

Glasdegib is currently being assessed in the phase III BRIGHT AML1019 trial (NCT03416179) in combination with intensive chemotherapy or in combination with azacitidine in patients with previously untreated AML.4

  1. European Commission approves Daurismo™ (glasdegib) for certain adult patients with newly diagnosed acute myeloid leukemia (AML). https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-daurismotm-glasdegib-certain. Published June 30, 2020. Accessed July 2, 2020.
  2. Clinicaltrials.gov. A study to evaluate PF-04449913 with chemotherapy in patients with acute myeloid leukemia or myelodysplastic syndrome. https://clinicaltrials.gov/ct2/show/record/NCT01546038. Updated March 3, 2020. Accessed July 2, 2020.
  3. Heuser M, Robak T, Montesinos P, et al. Glasdegib plus low-dose cytarabine in AML or MDS: BRIGHT AML 1003 final report and 4-year overall survival follow-up. e-poster #545. 2020 European Hematology Association 25th Annual meeting; Jun 12, 2020; Virtual.
  4. Clinicaltrials.gov. A study evaluating intensive chemotherapy with or without glasdegib or azacitidine with or without glasdegib in patients with previously untreated acute myeloid leukemia (BRIGHT AML1019). https://clinicaltrials.gov/ct2/show/NCT03416179. Updated May 27, 2020. Accessed July 2, 2020.

Share: